CM Management’s Compass Therapeutics CMPX Stock Holding History

CM Management’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.2M	Buy	+550,000	New	+$1.62M	0.77%	52
2026 Q1	–	Sell	-100,000	Closed	-$537K	–	73
2025 Q4	$537K	Sell	100,000 -50,000	-33%	-$231K	0.45%	52
2025 Q3	$525K	Buy	+150,000	New	+$474K	0.44%	57
2025 Q1	–	Sell	-310,000	Closed	-$450K	–	55
2024 Q4	$450K	Hold	310,000	–	–	0.4%	51
2024 Q3	$570K	Hold	310,000	–	–	0.46%	54
2024 Q2	$310K	Hold	310,000	–	–	0.28%	59
2024 Q1	$614K	Buy	310,000 +185,000	+148%	+$320K	0.52%	53
2023 Q4	$195K	Buy	+125,000	New	+$216K	0.16%	70
2022 Q3	–	Sell	-30,000	Closed	-$80K	–	73
2022 Q2	$80K	Sell	30,000 -270,000	-90%	-$586K	0.09%	69
2022 Q1	$411K	Buy	+300,000	New	+$620K	0.35%	67

Other funds holding CMPX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CM Management's CMPX Position: Q2 2026 in Review

CM Management opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 550,000 shares worth $1.2M. The stake represents 0.77% of the portfolio and ranks #52 among its holdings. This is a return to the name: CM Management previously reported a position in CMPX as recently as Q4 2025.

CM Management first reported a position in CMPX in Q1 2022 and has held it in 10 quarters since. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

CM Management held 550,000 shares of Compass Therapeutics worth $1.2M as of Q2 2026.
Compass Therapeutics was a new CM Management position in Q2 2026.
Compass Therapeutics made up 0.77% of CM Management's portfolio in Q2 2026, its #52 holding.
CM Management first reported a position in Compass Therapeutics in Q1 2022 and has held it in 10 quarters since.
216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on CM Management's 13F filing for Q2 2026, filed 13 Aug 2026.